PTC Therapeutics对可转换票据进行再融资定价

2026-06-16 16:38

PTC Therapeutics (PTCT) priced a private offering of $500M aggregate principal amount of 0% convertible senior notes due 2031, with an option for initial purchasers to buy an additional $50M of notes.
The sale of the notes is expected to close on June 18, 2026.
Net proceeds expected to be about $486.8M, or ~$535.5M if the option to purchase additional notes is exercised in full.
The new notes will be senior unsecured obligations that carry no regular interest and will mature on June 15, 2031. The notes will initially be convertible at a rate of 9.3042 shares per $1,000 principal amount, equivalent to a conversion price of about $107.48 per share, representing a 40% premium to PTC's June 15 closing price of $76.77.
The company plans to use about $328.8M to repurchase $222M aggregate principal amount of its existing 1.5% convertible senior notes due 2026 through privately negotiated transactions with current holders. The remaining proceeds will be used for general corporate purposes, including potential additional repurchases of the 2026 notes and repayment of any remaining balance at maturity.

More on PTC Therapeutics